Edinburgh Trials Methodology Hub
Lead Research Organisation:
University of Edinburgh
Department Name: School of Clinical Sciences
Abstract
When a new drug is being developed it passes through several stages of development. After the initial preclinical development, first in man studies evaluate the safety and potential side effects. Then explanatory studies optimise the treatment, for example in terms of which patients have the greatest potential to benefit and what dose to use. Such studies look at underlying disease mechanisms, and test whether an intervention has the potential to be useful in practice. Then pragmatic studies test whether any potential benefit seen in the explanatory trials can be realised in clinical practice. For non-drug treatments the terminology is different, but the development path is similar.
There are many reasons why an intervention can fail as it progresses through the stages of development, and the aim of the Edinburgh Trials Methodology Hub is to undertake a programme of research which will help to increase the chances of success at each step of the development process. We shall attempt to learn lessons both from successful development programmes and also from others which have failed.
This will be achieved by encouraging interdisciplinary cllaboration between the scientists who are working on understanding underlying disease mechanisms and those with experience in clinical trials methodology. The end results will be to improve the design and analysis of future clinical trials, and to provide researchers with trials support and access to genetic and imaging technologies to identify patient subgroups with the greatest potential to benefit within ongoing trials.
There are many reasons why an intervention can fail as it progresses through the stages of development, and the aim of the Edinburgh Trials Methodology Hub is to undertake a programme of research which will help to increase the chances of success at each step of the development process. We shall attempt to learn lessons both from successful development programmes and also from others which have failed.
This will be achieved by encouraging interdisciplinary cllaboration between the scientists who are working on understanding underlying disease mechanisms and those with experience in clinical trials methodology. The end results will be to improve the design and analysis of future clinical trials, and to provide researchers with trials support and access to genetic and imaging technologies to identify patient subgroups with the greatest potential to benefit within ongoing trials.
Technical Summary
Our vision is to deliver more effective translation of novel scientific ideas and discoveries (both drug and non-drug) into innovative clinical practice. A major challenge in clinical medicine is to identify therapeutic interventions that can be targeted to the correct patient at the right time to substantially improve disease outcomes. Traditionally, clinical trial design has focussed on delivering a standardised intervention on a large scale to patients with a specific clinical presentation which may actually have several different underlying causes, in terms of pathophysiology. This approach has been successful to an extent, but often these interventions have modest effects for the individual patient. Ideally therefore, one would wish to develop biomarkers which can be used in clinical practice to predict which patients will have the greatest response to an intervention, whilst excluding those who are likely to respond poorly or not at all. The vision of the Edinburgh Clinical Trials Methodology Hub will be to develop technologies to achieve this aim, by exploiting knowledge gained from animal models; by developing grid based networks for image analysis and processing; by exploiting access to genomic technologies and by developing a facility for secondary analysis of existing data to develop and validate prognostic models. The end result will be to improve the design of future clinical trials and to provide researchers access to imaging and genetic technologies to identify patient subgroups who respond best within ongoing trials.
In parallel with the planned methodological developments, the Edinburgh Hub will develop a training programme which combines elements of existing programmes in translational medicine, molecular medicine and public health sciences to develop the next generation of trialists and methodologists.
In parallel with the planned methodological developments, the Edinburgh Hub will develop a training programme which combines elements of existing programmes in translational medicine, molecular medicine and public health sciences to develop the next generation of trialists and methodologists.
Publications
Tudur Smith C
(2015)
How should individual participant data (IPD) from publicly funded clinical trials be shared?
in BMC medicine
Van Der Worp HB
(2010)
Can animal models of disease reliably inform human studies?
in PLoS medicine
Van Leeuwen N
(2012)
Prognostic value of major extracranial injury in traumatic brain injury: an individual patient data meta-analysis in 39,274 patients.
in Neurosurgery
Vesterinen HM
(2010)
Improving the translational hit of experimental treatments in multiple sclerosis.
in Multiple sclerosis (Houndmills, Basingstoke, England)
Vesterinen HM
(2013)
Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke.
in Systematic reviews
Walker J
(2010)
Screening for suicidality in cancer patients using Item 9 of the nine-item patient health questionnaire; does the item score predict who requires further assessment?
in General hospital psychiatry
Walker J
(2010)
The HSCL-20: one questionnaire, two versions.
in Journal of psychosomatic research
Walker J
(2013)
Prevalence of depression in adults with cancer: a systematic review
in Annals of Oncology
Walker J
(2014)
Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data
in The Lancet Psychiatry
Walker J
(2013)
Treatment of depression in people with lung cancer: A systematic review
in Lung Cancer
Walker J
(2014)
Treatment of depression in adults with cancer: a systematic review of randomized controlled trials.
in Psychological medicine
Walker S
(2014)
Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer.
in Psychological medicine
Wallia S
(2014)
Culturally adapting the prevention of diabetes and obesity in South Asians (PODOSA) trial.
in Health promotion international
Walsh T
(2013)
Restrictive Versus Liberal Transfusion Strategies for Older Mechanically Ventilated Critically Ill Patients A Randomized Pilot Trial*
in Critical Care Medicine
Walsh TS
(2015)
Increased Hospital-Based Physical Rehabilitation and Information Provision After Intensive Care Unit Discharge: The RECOVER Randomized Clinical Trial.
in JAMA internal medicine
Walsh TS
(2010)
Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units.
in Critical care medicine
Wardlaw JM
(2012)
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
in Lancet (London, England)
Waters RJ
(2013)
Cytokine gene polymorphisms and outcome after traumatic brain injury.
in Journal of neurotrauma
Weir J
(2012)
Does the extended Glasgow Outcome Scale add value to the conventional Glasgow Outcome Scale?
in Journal of neurotrauma
Whiteley W
(2012)
The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke.
in Stroke
Whiteley W
(2011)
Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study.
in Cerebrovascular diseases (Basel, Switzerland)
Whiteley W
(2009)
Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6.
in PLoS medicine
Whiteley WN
(2011)
Clinical scores for the identification of stroke and transient ischaemic attack in the emergency department: a cross-sectional study.
in Journal of neurology, neurosurgery, and psychiatry
Wu S
(2014)
Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review.
in International journal of stroke : official journal of the International Stroke Society
| Description | Arthritis Research UK |
| Amount | £756,791 (GBP) |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2010 |
| End | 06/2013 |
| Description | Arthritis Research UK |
| Amount | £723,692 (GBP) |
| Funding ID | 19403 |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2010 |
| End | 02/2016 |
| Description | CSO funding Health Services Research |
| Amount | £224,999 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 03/2013 |
| Description | CSO funding Health Sevices Research |
| Amount | £400,000 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2010 |
| End | 04/2012 |
| Description | Chief Scientist Office (CSO) |
| Amount | £47,030 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | EME Programme |
| Amount | £3,070,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2012 |
| End | 06/2014 |
| Description | HTA Programme |
| Amount | £2,140,000 (GBP) |
| Funding ID | 11/01/1930 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2012 |
| End | 05/2017 |
| Description | MRC Clinician Scientist Fellowship |
| Amount | £834,329 (GBP) |
| Funding ID | G0902303/95197 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2010 |
| End | 09/2015 |
| Description | MRC Efficacy and Mechanism Evaluation Programme (EME) |
| Amount | £1,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2010 |
| End | 06/2014 |
| Description | MRC Methodology Research Panel |
| Amount | £120,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2010 |
| End | 06/2012 |
| Description | MRC NIHR |
| Amount | £1,369,437 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2011 |
| End | 04/2016 |
| Description | Medical Research Council Clinician Scientist Fellowship |
| Amount | £834,329 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2010 |
| End | 09/2015 |
| Description | NIHR HTA |
| Amount | £485,908 (GBP) |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2011 |
| End | 08/2013 |
| Description | NIHR HTA |
| Amount | £2,940,842 (GBP) |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Project Grant |
| Amount | £1,340,000 (GBP) |
| Funding ID | SP/12/2/29422 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2013 |
| End | 05/2018 |
| Title | Ordinal Analysis of Clinical Trial Outcomes |
| Description | A number of methodological studies, now supported by relevant publications, have demonstrated the strengths and limitations of ordinal analysis in clinical trials of head injury and stroke. |
| Type Of Material | Data analysis technique |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | An ordinal approach has been adopted as the primary analytical approach in a number of on-going clinical trials. |
| Description | Edinburgh Clinical Trials Unit |
| Organisation | University of Edinburgh |
| Department | Edinburgh Clinical Trials Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The senior statisticians with the Hub work closely with the Trials Unit, giving statistical input for trial protocols and grant applications. |
| Collaborator Contribution | The collaboration has been a source of research questions for the Merthodology Hub and given the opportunity to evaluate and promote methodological developments emerging from the Methodology Hub. |
| Impact | The principal outputs to date have been grant applications for clinical trials which have been funded - including awards through MRC EME, Arthritis Research UK, and CSO. |
| Start Year | 2009 |
| Description | Scottish Mental Health Research Network |
| Organisation | Scottish Mental Health Research Network (SMHRN) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Hub statisticians are involved in giving statistical advice to researchers via the SMHRN's Protocol Development Groups. |
| Collaborator Contribution | The protocols developed via the SMHRN provide a source of methodological research problemsand also a testbed for methodological innovations. |
| Impact | The outputs to date have been grant applications being worked up for submission. |
| Start Year | 2009 |
| Description | Scottish eHealth Informatics Research Centre |
| Organisation | Scottish School of Primary Care |
| Department | Scottish eHealth Informatics Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is at a very early stage, with the eHIRC just having been funded. |
| Collaborator Contribution | Sheikh is a grant holder for the eHIRC. The grant application to extend the Hub funding beyond 2013 has eHealth as a major research theme. |
| Impact | It is too early for this collaboration to have produced outputs |
| Start Year | 2012 |